Imatinib and hypophosphatemia: Case report and review of literature
Imatinib mesylate is a potent inhibitor of the BCR-Abl kinases, c-Kit, PDGFR, and fms. Imatinib used for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor. Imatinib has been well tolerated. The most common adverse events reported included edema, nausea, diarrhea, myalgia or mu...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Turkiye Klinikleri
2017-07-01
|
| Series: | Journal of Oncological Sciences |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452336417300031 |